---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000080"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:20:06.455378+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Salarius Pharma expects Q2 net loss ~$900K, cash $800K; raises $3.8M via equity line

## Summary
- Preliminary Q2 2025 net loss ~$900,000; cash at June 30 was $800,000.
- Issued 5.5M shares under equity line for ~$3.8M gross proceeds post-quarter.
- As of July 30, 2025, pro forma cash ~$4.5M after issuance.
- Unregistered sale to C/M Capital Master Fund LP under purchase agreement.
- Preliminary results are subject to adjustment; not yet audited.

## SEC filing metadata
- accession: 0001615219-25-000080
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000080/0001615219-25-000080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000080/flks-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000080
- JSON: https://secwatch.observer/filing/0001615219-25-000080.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.